Wuhan Healthgen Biotechnology CorpSSE: 688765

(688765)"WUHAN HEALTHGEN BIOTECHNOLOGY CORP."Report for Q3 2026

· Issued by Wuhan Healthgen Biotechnology Corp via Shanghai Stock Exchange

Filed with SSE · Stock code 688765 · · 13 pages · Chinese

Summary by 6ix AI

The report highlights that the financial statements have not been audited and includes key financial data such as revenue and net profit figures. It also discusses the company's ongoing clinical trials and research projects, particularly focusing on the drug 奥福民 and its development progress. The report emphasizes the company's commitment to transparency and accuracy in its financial disclosures and operational updates.

Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries

Wuhan Healthgen Biotechnology Corp on 6ix

Earlier from Wuhan Healthgen Biotechnology

Later from Wuhan Healthgen Biotechnology

All Wuhan Healthgen Biotechnology news releases